Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

• Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, John K., Lakomy, David S., McDonald, Yassmina, Kapp, Daniel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292902/
https://www.ncbi.nlm.nih.gov/pubmed/32551353
http://dx.doi.org/10.1016/j.gore.2020.100581
_version_ 1783546189567754240
author Chan, John K.
Lakomy, David S.
McDonald, Yassmina
Kapp, Daniel S
author_facet Chan, John K.
Lakomy, David S.
McDonald, Yassmina
Kapp, Daniel S
author_sort Chan, John K.
collection PubMed
description • Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects.
format Online
Article
Text
id pubmed-7292902
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72929022020-06-17 Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer Chan, John K. Lakomy, David S. McDonald, Yassmina Kapp, Daniel S Gynecol Oncol Rep Case Report • Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects. Elsevier 2020-05-26 /pmc/articles/PMC7292902/ /pubmed/32551353 http://dx.doi.org/10.1016/j.gore.2020.100581 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Chan, John K.
Lakomy, David S.
McDonald, Yassmina
Kapp, Daniel S
Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title_full Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title_fullStr Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title_full_unstemmed Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title_short Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
title_sort long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292902/
https://www.ncbi.nlm.nih.gov/pubmed/32551353
http://dx.doi.org/10.1016/j.gore.2020.100581
work_keys_str_mv AT chanjohnk longtermdurableresponsesafterpembrolizumabimmunotherapyforrecurrentresistantendometrialcancer
AT lakomydavids longtermdurableresponsesafterpembrolizumabimmunotherapyforrecurrentresistantendometrialcancer
AT mcdonaldyassmina longtermdurableresponsesafterpembrolizumabimmunotherapyforrecurrentresistantendometrialcancer
AT kappdaniels longtermdurableresponsesafterpembrolizumabimmunotherapyforrecurrentresistantendometrialcancer

Ejemplares similares